Schiedlberg

Researchers are evaluating the safety and effectiveness of the recoveriX PRO system, a Brain-Computer Interface (BCI) device, in improving motor functions in patients with Parkinson's Disease. This system combines Motor Imagination (MI) with Functional Electrical Stimulation (FES) and Virtual Reality (VR) feedback, using an EEG cap to monitor brain activity during mental practice. The study aims to compare this BCI-based treatment to a standard therapy involving MI, FES, and VR without EEG monitoring, focusing on motor function improvement and safety. Participants are divided into two groups: one receives 24 sessions of recoveriX therapy over 4 weeks (6 sessions per week), involving BCI-based motor imagery with FES and VR feedback. The control group undergoes 24 sessions of standard FES and VR therapy combined with MI but without the EEG cap. Both treatments provide similar stimulation amounts, aiming to assess differences in functional gains. During the study, participants will be assessed twice before treatment (at week 0 and week 1) and twice after treatment (at week 5 and week 7) using motor skill evaluations, walking ability tests, fatigue assessments, and daily living impact questionnaires. Researchers will monitor motor function changes using the Movement Disorders Society Unified Parkinson's Disease Rating Scale Section III and track safety throughout the trial. The total participation period includes pre- and post-intervention assessments surrounding the 4-week treatment phase.